Author

Severine Vermeire

IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Severine Vermeire  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Severine Vermeire  et al.

IMPACT OF PRIOR BIOLOGIC EXPOSURE ON THE DURABILITY OF 3-YEAR CONTINUOUS OZANIMOD TREATMENT
IMPACT OF PRIOR BIOLOGIC EXPOSURE ON THE DURABILITY OF 3-YEAR CONTINUOUS OZANIMOD TREATMENT

Severine Vermeire  et al.

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

Drugs of the future
Drugs of the future

Severine Vermeire

EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

Severine Vermeire  et al.

Predictors of response IBD
Predictors of response IBD

Severine Vermeire

JAK of all trades, master of IBD? Refocusing our clinical expectations (AbbVie)
JAK of all trades, master of IBD? Refocusing our clinical expectations (AbbVie)

Severine Vermeire  et al.

Trial design and endpoints: Novelty, confusion or smoke and mirrors?
Trial design and endpoints: Novelty, confusion or smoke and mirrors?

Severine Vermeire

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY
BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire

CORTICOSTEROID-FREE REMISSION OF ULCERATIVE COLITIS WITH FILGOTINIB MAINTENANCE THERAPY: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
CORTICOSTEROID-FREE REMISSION OF ULCERATIVE COLITIS WITH FILGOTINIB MAINTENANCE THERAPY: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Severine Vermeire  et al.

IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION
IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION

Severine Vermeire  et al.

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Severine Vermeire  et al.

TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Severine Vermeire  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Severine Vermeire  et al.

MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL

Severine Vermeire  et al.

HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Severine Vermeire  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Severine Vermeire  et al.

SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS
SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS

Severine Vermeire  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

Severine Vermeire  et al.

Item 21 - 40 / 80
1
2
3 4